Claire Mazumdar
Chief Executive Officer at Bicara Therapeutics Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 3 years
- Director since
- 2024
3 years of board service in total across 2 boards, counting each seat separately. Longest: Bicara Therapeutics Inc., 2 years.
Bicara Therapeutics Inc.
Director · Chief Executive Officer
Relay Therapeutics Inc.
Director
Chief executive roles
Bicara Therapeutics Inc.
· Chief Executive Officer
Since September 2024
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 10, 2026 | Bicara Therapeutics Inc. | Option exercise | +10,000 | $3.79 | $37,898 |
| Aug 10, 2026 | Bicara Therapeutics Inc. | Open-market sale | −10,000 | $27.98 | $279,750 |
| Jul 10, 2026 | Bicara Therapeutics Inc. | Option exercise | +10,000 | $3.79 | $37,898 |
| Jul 10, 2026 | Bicara Therapeutics Inc. | Open-market sale | −9,972 | $28.42 | $283,367 |
| Jul 10, 2026 | Bicara Therapeutics Inc. | Open-market sale | −28 | $29.68 | $831 |
| May 18, 2026 | Bicara Therapeutics Inc. | Option exercise | +15,000 | $3.79 | $56,850 |
| May 18, 2026 | Bicara Therapeutics Inc. | Open-market sale | −12,022 | $19.96 | $239,959 |
| May 18, 2026 | Bicara Therapeutics Inc. | Open-market sale | −2,978 | $20.35 | $60,602 |
| Apr 20, 2026 | Bicara Therapeutics Inc. | Option exercise | +15,000 | $3.79 | $56,850 |
| Apr 20, 2026 | Bicara Therapeutics Inc. | Open-market sale | −15,000 | $23.61 | $354,150 |
| Apr 16, 2026 | Bicara Therapeutics Inc. | Option exercise | +8,226 | $4.44 | $36,523 |
| Apr 16, 2026 | Bicara Therapeutics Inc. | Option exercise | +7,454 | $3.79 | $28,251 |
| Apr 16, 2026 | Bicara Therapeutics Inc. | Option exercise | +7,080 | $5.45 | $38,586 |
| Mar 20, 2026 | Bicara Therapeutics Inc. | Option exercise | +1,596 | $3.79 | $6,049 |
| Mar 20, 2026 | Bicara Therapeutics Inc. | Open-market sale | −1,596 | $18.95 | $30,244 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.